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Background and purpose   There have been few long-term stud-
ies on the outcome of chondrosarcoma and the findings regard-
ing prognostic factors are controversial. We examined a homoge-
neous group of patients with primary central chondrosarcoma of 
bone who were treated according to a uniform surgical protocol 
at our institution, in order to determine the factors that influence 
survival and identify potential improvements to our therapeutic 
algorithm.
Patients and methods   We performed a retrospective analy-
sis of 115 patients with primary central chondrosarcoma of bone 
who presented with localized disease and who had a minimum 
follow-up of 5 years after diagnosis. 68 tumors were localized in 
the extremities and 47 in the axial skeleton or pelvis. 59 patients 
had a high-grade (II and III) and 56 a low-grade (I) tumor. 94 
patients underwent surgical resection with adequate (wide or 
radical) margins, while 21 patients had inadequate (marginal or 
intralesional) margins. 
Results   Tumor grade and localization were found to be statisti-
cally significant independent predictors of disease-related deaths 
in multivariate analysis. The quality of surgical margins did not 
influence survival. The AJCC staging system was able to pre-
dict prognosis in patients with chondrosarcoma of the extremi-
ties, but not in those with tumors of the axial skeleton and pelvis. 
Long-term survival after secondary metastatic disease was only 
observed when metastases were resected with wide margins. 
Patients with metastases who received further treatment with 
conventional chemotherapy, radiotherapy, and/or further surgery 
had significantly better survival compared to those who received 
best supportive care. 
Interpretation   The outcome in patients with primary central 
chondrosarcoma of bone who present with localized disease is 
mostly affected by tumor-related parameters. 

Chondrosarcoma is the second most common primary malig-
nant solid tumor of bone, and accounts for approximately 
25% of all bone sarcomas (Bertoni et al. 2002). It is largely 
considered to be resistant to conventional chemotherapy and 
radiotherapy (Healey and Lane 1986, Campanacci 1999, Gel-
derbloom et al. 2008). As such, surgical resection has been the 
cornerstone of treatment for over 50 years (Dahlin and Hen-
derson 1956, Healey and Lane 1986, Gelderbloom et al. 2008). 
However, in recent years several novel therapeutic approaches 
have been evaluated in experimental studies (Morioka et al. 
2003, Gouin et al. 2006, Klenke et al. 2007, Delaney et al. 
2009, Schrage et al. 2009, 2010). 
There is no consensus on prognostic factors to determine 
which patients have a higher risk of treatment failure and dis-
ease-related deaths, although several papers have addressed 
this issue (Evans et al. 1977, Pritchard et al. 1980, Gitelis 
et al. 1981, Björnsson et al. 1998, Lee et al. 1999, Rizzo et 
al. 2001, Fiorenza et al. 2002). One reason may be that most 
studies have included patients treated over several decades, 
with no account for the different surgical criteria, indications, 
and methods applied over the years. Furthermore, most stud-
ies have included patients with short follow-up, despite the 
fact that a high rate of late recurrence and metastasis has been 
reported for chondrosarcoma patients compared to those with 
other primary bone sarcomas (Evans et al. 1977, Pritchard et 
al. 1980), as well as patients with rare histopathological sub-
types that have a distinct biologic behavior (Lee et al. 1999, 
Bertoni et al. 2002, Gelderbloom et al. 2008) such as dedif-
ferentiated chondrosarcoma, mesenchymal chondrosarcoma, 
and clear cell chondrosarcoma, thus reducing the validity of 
the results. 
The purpose of this long-term retrospective study was to 
examine a group of patients with primary central chondrosar-
coma of bone who presented with localized disease and were 
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in order to determine the factors that influence overall and 
event-free survival. We further aimed at identifying potential 
improvements to our therapeutic algorithm. 
Patients and methods
146 patients with primary central chondrosarcoma of bone 
presenting with localized disease were treated at our sar-
coma department between 1982 and 2004. 31 patients were 
excluded from this analysis—6 patients who were primarily 
treated with palliative intent and 25 patients with follow-up of 
less than 5 years after diagnosis—leaving 115 patients for this 
study. At hospital admission, all patients had signed a consent 
form allowing the use of anonymized information for research 
purposes.
There were 70 male and 45 female patients. The mean age at 
presentation was 47 (14–79) years and 81 patients were older 
than 40 years (Table 1). The mean follow-up period for survi-
vors was 12 (5–24) years. Follow-up data were obtained at our 
outpatient clinic or by telephone calls to referring physicians. 
48 tumors were located in the lower extremity, 42 in the 
pelvic girdle, 20 in the upper extremity or shoulder girdle, and 
5 in the axial skeleton. 8 patients presented with a pathological 
fracture in the lower (n = 5) or upper (n = 3) extremity. Tumor 
volume was assessed by the pathologist during examination of 
the surgical specimen. Recorded for 93 patients, it had a mean 
of 396 (1–3,827) cm3.
56 patients (49%) were diagnosed with grade I tumors, 
41 patients (36%) with grade II, and 18 patients (15%) with 
grade III tumors. The grading was based on the system pro-
posed by Evans et al. (1977). Cartilage tumors of borderline 
malignancy were not included in this series. According to the 
American Joint Committee on Cancer (AJCC) staging system 
(Greene et al. 2002), 31 patients had stage IA tumors (27%), 
23 patients stage IB (20%), 10 patients stage IIA (9%), and 51 
patients stage IIB tumors (44%). For the statistical analysis, 
grade II and grade III tumors were classified as high-grade, 
while grade I tumors were classified as low-grade.
All patients underwent surgical treatment of the primary 
tumor. Customized megaprostheses became available at our 
institution in 1982. Since then, our surgical protocol has 
undergone only minor alterations, consistently involving the 
curettage of small, low-grade tumors of the extremities with-
out infiltration of the soft tissue, and a planned wide resection 
followed by a biological or endoprosthetic reconstruction—
when necessary—for all other tumors. Amputations were 
performed when limb-sparing procedures with wide surgical 
margins and preservation of a functional limb were deemed 
impossible, mainly due to tumor infiltration of neurovascu-
lar structures or extensive soft tissue infiltration, unless the 
patient declined to undergo a mutilating procedure. 
Surgical margins were divided into intralesional, marginal, 
wide and radical, according to the classification of Enneking. 
For the purposes of this analysis, intralesional and marginal 
margins, documented in 21 patients (18%), were characterized 
as inadequate. Among them were 11 patients in whom a wide 
resection was initially planned; 4 of these patients underwent a 
wide re-resection, while 1 patient received adjuvant radiation 
therapy with 60 Gy. Wide and radical margins, documented 
in 94 patients (82%), were characterized as adequate surgical 
margins. 77 patients with tumors of the extremities or pelvic 
girdle underwent limb-sparing surgery, while 33 patients were 
amputated. 
A local recurrence developed in 38 patients (33%) after a 
mean of 21 (2–96) months. In 2 of these patients, the tumor 
had dedifferentiated. Distant metastasis developed in 30 
patients (26%) after a mean of 27 (2–141) months. 19 patients 
(17%) developed both a local recurrence and distant metasta-
ses at some stage of their illness.
Statistics
Survival analysis was performed using the Kaplan-Meier 
method. Overall survival was calculated from the date of 
diagnostic biopsy until death related to disease or treatment, 
and event-free survival from the date of tumor resection until 
disease recurrence or death. Survival curves were compared 
using the log-rank test. Taking into account the different chal-
lenges in surgical treatment of tumors of the axial skeleton and 
pelvic girdle compared to tumors of the extremities, as well as 
the differences in the clinical course of low- and high-grade 
tumors, overall and event-free survival were calculated sepa-
rately for these groups. We performed a multivariate analysis 
with the Cox proportional hazards model to identify indepen-
dent predictors of survival in the entire group. The variables 
entered into this model were the ones previously examined in 
the literature, in order to permit a direct and consistent com-
parison of our results with the results of earlier studies. The 
proportional hazards assumption was checked by plotting the 
logarithm of the cumulative hazards functions for each covari-
ate, with parallel curves supporting the proportional hazards 
assumption. The continuous covariate age was categorized 
with a cutoff at 40 years. All statistical analyses were carried 
out using the SPSS software version 16.0 (SPSS, Inc., Chi-
cago, IL). All tests were 2-sided. A p-value of less than 0.05 
was considered significant.
Table 1. Distribution of patient age
Patient age   n  %
14–20   9  8
21–30  8 7
31–40   17  15
41–50   26  22
51–60   33  29
61–70   16  14
71–79   6  5Acta Orthopaedica 2011; 82 (6): 749–755  751
Results
At the time of this analysis, 73 patients were alive with no evi-
dence of disease. 32 patients had died from disease, 6 patients 
from treatment-related complications and 4 patients from 
other causes. Overall survival rates of the entire group at 5 and 
10 years were 72% and 69%, respectively. Event-free survival 
at 5 and 10 years amounted to 57% and 53%, respectively. 
Both overall (Figure 1) and event-free survival were statisti-
cally significantly better for patients with chondrosarcomas of 
the extremities (E group) than for those with tumors of the 
axial skeleton and pelvic girdle (AP group) (Table 2). 
No statistically significant difference was detected in the 
survival of male and female patients (Table 2). On the other 
hand, age at diagnosis had a statistically significant impact on 
overall survival. With a cutoff at 40 years, younger patients 
faired better than older ones (Table 2). Patients with a tumor 
volume lower than 100 cm3 had a statistically significantly  Figure 1. The impact of tumor location on overall survival.
Table 2. Univariate analysis of overall and event-free survival
  Overall survival (%)  Event-free survival (%)
  Patients 5-year 10-year p-value  a  5-year 10-year p-value  a
Entire group  115  72  69      57  53
 AP  b  47  60  55  0.002  40  38  0.004
 E  c  68  81  79     68  63
  Low-grade  56  89  89  < 0.001    73  68  < 0.001
 High-grade  59  56  50      41  39
Age
  ≤ 40 years  34  85  82  0.04    62  55  0.6
  > 40 years  81  67  64      54  52
Sex
 Male  70  73  68  0.6    56  52  0.9
 Female  45  71  71      58  54
Tumor volume in cm3
  0–100  36  92  89  < 0.001    81  76  0.007
 100–200  18  50  50      44  44
 100–200  18  50  50  1.0    44  44  1.0
   > 200  39  61  58      46  43
Local recurrence
  No  77  83  83  < 0.001
 Yes  38  47  42
  AP – No   27  74  74  0.005
  AP – Yes   20  40  29
  E – No   50  90  88  < 0.001
  E – Yes   18  56  56
  Low-grade – No   41  95  95  0.008
  Low-grade – Yes   15  73  73
  High-grade – No   36  72  69  < 0.001
  High-grade – Yes   23  30  21
Distant metastasis
  No  85  89  89  < 0.001
 Yes  30  23  13
  AP – No   29  76  76  < 0.001
  AP – Yes   18  33  22
  E – No   56  96  96  < 0.001
  E – Yes   12  8  0
  Low-grade – No   53  94  94  < 0.001
  Low-grade – Yes   3  0  0
  High-grade – No   32  81  81  < 0.001
  High-grade – Yes   27  26  15
better overall and event-free sur-
vival than those with a tumor 
volume of between 100 cm3 
and 200 cm3. The influence of 
volume on survival was dimin-
ished in tumors greater than 100 
cm3 (Table 2). 
A high tumor grade had a 
statistically significant nega-
tive impact on both overall and 
event-free survival. The influ-
ence on overall survival was far 
more pronounced in the E group 
than in the AP group (Table 2), 
probably due to the worse sur-
vival of patients with low-grade 
tumors in the axial skeleton or 
pelvis compared to the survival 
of those with low-grade tumors 
of the extremities. Regarding 
event-free survival, only 1 of 10 
patients with a grade-III tumor 
in the AP group remained event-
free at 5 years and none remained 
event-free at 10 years (Table 2).
The quality of surgical margins 
did not significantly affect over-
all or event-free survival (Figure 
2), regardless of tumor grade 
or localization  (Table 2). How-
ever, subgroup analysis revealed 
an improved, but not statisti-
cally significant, event-free and 
overall survival for patients 
with adequate margins in the 
AP group. Survival was similar 752  Acta Orthopaedica 2011; 82 (6): 749–755
between limb-sparing and ablative procedures (Table 2). The 
presence of a pathological fracture at diagnosis led to a sta-
tistically significant decline in overall survival in the entire 
E group; however, subgroup analysis showed the significance 
to be restricted to patients with tumors of the lower extremity 
(Table 2). 
The AJCC staging system correlated both with overall 
(Figure 3A) and with event-free survival in the entire group 
(Table 2). This correlation was very strong only in patients 
Cox proportional hazards regression model. The presence of 
a pathological fracture at diagnosis was excluded from the 
multivariate analysis, since this factor appeared only in the E 
group. Significant independent predictors of death were high 
grade (relative risk (RR) = 5, 95% CI: 2–12; p < 0.001) and 
a tumor localization in the axial skeleton and pelvis (RR = 2, 
95% CI: 1–4; p = 0.04). 
 
Table 2 continued.
  Overall survival (%)  Event-free survival (%)
  Patients 5-year 10-year p-value  a  5-year 10-year p-value  a
Tumor grade
  G1  56  89  89  < 0.001    73  68  < 0.001
 G2  41  63  58      49  49
 G3  18  39  33      22  15
  AP – G1  18  72  72  0.04    56  56  0.001
  AP – G2  19  58  53      42  42
  AP – G3  10  40  30      10  0
  E – G1  38  97  97  < 0.001    82  74  0.02
  E – G2  22  68  63      54  54
  E – G3  8  38  38      38  38
Surgical margins
 Inadequate  21  71  67  0.9    48  33  0.2
 Adequate  94  72  70      59  57
  AP – Inadequate  6  33  17  0.1    0  0  0.08
  AP – Adequate  41  63  61      46  44
  E – Inadequate  15  87  87  0.4    67  46  0.4
  E – Adequate  53  79  77      68  68
  Low-grade – Inadequate  13  85  85  0.7    69  43  0.2
  Low-grade – Adequate  43  91  91      74  74
  High-grade – Inadequate   8  50  38  0.8    13  13  0.3
  High-grade – Adequate  51  57  52      45  43
Type of surgery                 
  Low-grade – ablative  6  100  100  0.7    67  67  0.9
  Low-grade – limb-sparing  46  89  89      74  68
  High-grade – ablative  27  52  43  0.1    37  32  0.4
  High-grade – limb-sparing  31  58  58      45  45 
Pathological fracture
  E – No  60  85  85  0.002    72  66  0.1
  E – Yes  8  50  38      38  38 
  Lower extremity – No   43  86  86  < 0.001    67  67  0.07
  Lower extremity – Yes   5  40  20      40  20
  Upper extremity – No   17  82  82  0.4    82  64  0.7
  Upper extremity – Yes   3  67  67      67  67
Tumor stage (AJCC)
  Ia  31  90  90  < 0.001    81  72  0.004
 Ib  23  87  87      65  65
 IIa  10  50  50      50  50
  IIb   51  59  53      39  37
  AP – Ia  7  57  57  0.1    57  57  0.3
  AP – Ib    11  82  82      55  55
  AP – IIa   5  20  20      20  20
  AP – IIb    24  58  50      33  29
  E – Ia  24  100  100  0.001    88  76  0.02
  E – Ib    12  92  92      75  75
  E – IIa   5  80  80      80  80
  E – IIb    27  59  55      44  44
a (log-rank)
b AP: chondrosarcoma of the axial skeleton and pelvic girdle; 
c E: chondrosarcoma of the extremity.
with chondrosarcoma of the 
extremities (Figure 3B). The 
staging system failed to allow 
accurate prediction of prognosis 
in patients with chondrosarcoma 
of the axial skeleton or pelvis 
(Figure 3C and Table 2).
Both the development of local 
recurrence and the development 
of distant metastases led to a 
significant decline in overall sur-
vival, regardless of tumor grade 
or localization (Table 2). A local 
recurrence preceded the diagno-
sis of metastatic disease in 10 of 
30 patients. Metastatic disease 
was documented in 3 patients 
with initially grade I tumors 
initially, all of whom had previ-
ously developed a high-grade 
local recurrence without dedif-
ferentiation and all of whom died 
of their disease. Further analysis 
of the 30 patients with metas-
tases revealed that long-term 
survival was observed only in 
patients who had undergone sur-
gical resection of all metastases 
with wide margins. Patients who 
received further treatment with 
conventional multidisciplinary 
treatment plans, including stan-
dard systemic chemotherapy, 
radiotherapy, and/or further sur-
gery had better survival than 
those who received best support-
ive care (p = 0.001) (Figure 4). 
In an attempt to identify inde-
pendent predictors of survival 
at the time of diagnosis, tumor 
localization and grade, patient 
age, sex, and the quality of sur-
gical margins were submitted 
to multivariate analysis with the Acta Orthopaedica 2011; 82 (6): 749–755  753
Discussion
One of the most interesting findings in our series concerns 
the quality of surgical margins. No effect could be shown on 
overall survival, both in univariate and in multivariate analy-
sis, although a strong trend of improved survival was found in 
the AP group for adequate margins. At first, this finding seems 
to contradict previous studies, which demonstrated that inade-
quate surgical margins were associated with poorer prognosis 
(Gitelis et al. 1981, Lee et al. 1999, Rizzo et al. 2001, Fiorenza 
et al. 2002). However, a systematic review of the literature 
revealed only 2 studies that included a multivariate analysis 
for factors affecting survival (Lee et al. 1999, Fiorenza et al. 
2002). Inadequate surgical margins were shown to have only 
minimal influence on overall survival in the first study and no 
influence in the second. As both studies found that the devel-
Figure 2. Overall survival (A) and event-free survival (B), according to 
surgical margins.
Figure 3. Overall survival in the entire group (A), the E group (B), and 
the AP group (C) according to the AJCC staging system.
A A
B B
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Figure 4. Overall survival following the development of metastatic dis-
ease, according to further treatment.
opment of local recurrence was associated with worse overall 
survival and that inadequate surgical margins led to a higher 
rate of local recurrence (findings we were able to confirm in 
our data), the authors postulated that there may be an associa-
tion between inadequate margins and worse overall survival 
(Lee et al. 1999, Fiorenza et al. 2002). In light of our results, 
we believe this is not the case. It has long been shown in soft 
tissue sarcoma that studies addressing the issue of diminishing 
local recurrence in a prospective, randomized fashion—such 
as was done with radiotherapy—did not lead to any survival 
benefit (Brennan 2007), although it should be noted that no 
analogous studies have been conducted in chondrosarcoma 
patients. On these grounds, it has been hypothesized that not 
all local recurrences are the same (Brennan 2007) and that 
the development of local recurrence after adequate treatment 
might be a marker of an aggressive tumor that is more likely to 
metastasize (Brennan 1997, Gronchi et al. 2007). This, how-
ever, may not be the case for local recurrences after intral-
esional or marginal resections, at least in soft tissue sarcomas 
(Brennan 2007). 
Given that the development and subsequent treatment of 
a local recurrence can lead to increased morbidity and com-
promise functional outcome, we do not suggest that these 
results can justify inadequate surgery of otherwise resectable 
tumors—with the exception of small, low-grade tumors of the 
extremities without infiltration of the soft tissue. However, we 
do think that, in light of these findings, the role of ablative sur-
gery in patients with locally advanced tumors of the extremi-
ties for which a limb-sparing resection with wide margins is 
deemed risky should be examined further. This especially so 
in patients who refuse amputation or in patients for whom a 
secondary amputation is recommended after inadequate resec-
tion of the primary tumor, as there was no correlation between 
type of surgery and outcome in our patient cohort. 
Another surprising finding was that the AJCC staging 
system did not correlate with oncological outcome in patients 
with tumors of the axial skeleton or pelvis. To our knowledge, 
this has not been reported previously. The reasons for this are 
unclear. The retrospective nature of our study did not allow 
an evaluation of the Musculoskeletal Tumor Society (MSTS) 
staging system, as accurate data regarding tumor compart-
mentalization were missing in many cases. Heck et al. (2003) 
found a similar prognostic significance of the AJCC and the 
MSTS staging systems in patients with primary malignant 
bone tumors, but subgroup analysis according to tumor local-
ization was not performed. We believe that further studies 
including all primary bone sarcomas of the pelvis and axial 
skeleton are warranted; if our results are confirmed, the devel-
opment of a separate staging system for these tumors would 
be justified. A possible alternative to tumor size might be 
tumor volume, with a cutoff at 100 cm3, as it was shown to 
be an important predictor of overall and event-free survival. 
With volumetric data missing in 7 out of 47 patients in the 
AP group, such an alternative staging system correlated better 
with overall and event-free survival in our series—but also 
failed to reach statistical significance (data not shown). 
A dismal prognosis after development of secondary meta-
static disease has been reported in many studies (Björnsson 
et al. 1998, Lee et al. 1999, Rizzo et al. 2001, Fiorenza et al. 
2002). In our series, long-term survival was possible only for 
patients who underwent surgical resection with adequate mar-
gins, as has already been described for osteosarcoma patients 
(Kempf-Bielack et al. 2005). Moreover, further treatment pro-
longed survival of patients with metastasis compared to best 
supportive care. However, the small patient sample, the vari-
ety of treatment protocols used for metastatic disease at our 
institution over the years, and the retrospective design of the 
study preclude any definitive conclusions.
3 of the 56 patients with initially grade I chondrosarcoma 
developed metastasis and died of their disease within 5 years. 
Several series examining the course of grade I chondrosar-
coma have reported similar results, i.e. a low risk of meta-
static disease but high mortality rates after metastasis ranging 
from 70% to 100% (Leerapun et al. 2007, Schwab et al. 2007, 
Streitbürger et al. 2009). It appears that the development of 
metastasis in these patients is suggestive of a highly aggres-
sive disease phenotype. 
The presence of a pathological fracture at diagnosis led to a 
statistically significant decrease in overall survival in patients 
with chondrosarcoma of the lower extremity, but not in those 
with tumors of the upper extremity. Lee et al. (1999) found 
similar survival rates in patients with or without pathological 
fracture, while Bramer et al. (2007) found a statistically sig-
nificant decrease in univariate analysis, but not in multivariate 
analysis. Neither study distinguished between tumors of the 
lower and the upper extremity; it would be interesting to see 
whether tumor localization influences the prognostic impact 
of a pathological fracture in a larger series.Acta Orthopaedica 2011; 82 (6): 749–755  755
In conclusion, the outcome of patients with primary central 
chondrosarcoma of bone who present with localized disease 
is mostly affected by tumor- and patient-related parameters. 
There appear to be subgroups of patients who might benefit 
from modifications in the standard practice, including those 
who have traditionally been considered as candidates for abla-
tive surgery, as well as those with distant metastasis who are 
unwilling or unable to participate in phase II clinical trials. 
The AJCC staging system does not appear to accurately pre-
dict the risk of disease-specific mortality for all subgroups of 
patients.
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